Stockscreener 앱 받기
13.08
4.08%
0.46
전일 마감가:
$12.62
열려 있는:
$13.12
하루 거래량:
1.98M
Relative Volume:
0.28
시가총액:
$1.40B
수익:
$52.86M
순이익/손실:
$-480.19M
주가수익비율:
-2.789
EPS:
-4.6899
순현금흐름:
$-421.82M
1주 성능:
-11.19%
1개월 성능:
-34.19%
6개월 성능:
+48.59%
1년 성능:
-11.31%
1일 변동 폭
$13.00
$13.60
1주일 범위
$11.63
$14.79
52주 변동 폭
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
명칭
Intellia Therapeutics Inc
전화
857-285-6200
주소
40 ERIE STREET, CAMBRIDGE, MA
NTLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
13.03 | 1.35B | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.60 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
646.39 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.93 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
827.92 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.70 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-28 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | 개시 | H.C. Wainwright | Buy |
| 2025-02-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-02-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-04-13 | 개시 | Canaccord Genuity | Buy |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-03-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-24 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-01-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Sell |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-06-16 | 개시 | BofA Securities | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-02-18 | 개시 | William Blair | Outperform |
| 2022-02-07 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-31 | 개시 | Cowen | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
| 2021-10-05 | 개시 | Guggenheim | Buy |
| 2021-09-24 | 개시 | Stifel | Buy |
| 2021-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-11 | 개시 | H.C. Wainwright | Buy |
| 2021-05-07 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | 개시 | Truist | Buy |
| 2020-10-14 | 개시 | Wells Fargo | Overweight |
| 2020-09-18 | 개시 | Goldman | Buy |
| 2020-02-28 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-14 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-11-01 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | 개시 | Robert W. Baird | Outperform |
| 2019-06-10 | 개시 | ROTH Capital | Neutral |
| 2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-11-02 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-10-29 | 개시 | Credit Suisse | Neutral |
| 2018-09-21 | 개시 | Raymond James | Mkt Perform |
| 2018-05-15 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | 개시 | JMP Securities | Mkt Outperform |
| 2017-11-01 | 재확인 | Jefferies | Buy |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-05 | 업그레이드 | Jefferies | Hold → Buy |
모두보기
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Chart overlay techniques for tracking Intellia Therapeutics Inc.2025 Historical Comparison & Accurate Intraday Trade Tips - newser.com
How sentiment analysis helps forecast Intellia Therapeutics Inc.Market Growth Report & Growth Oriented Trade Recommendations - newser.com
Real time scanner hits for Intellia Therapeutics Inc. explainedQuarterly Trade Summary & Weekly Chart Analysis and Trade Guides - newser.com
How cyclical is Intellia Therapeutics Inc. (38I) stock compared to rivalsJuly 2025 WrapUp & Weekly Watchlist of Top Performers - newser.com
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130% - sharewise.com
Should You Buy Viking Therapeutics Before Nov. 5? - AOL.com
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130% - The Motley Fool
Is Intellia Therapeutics Inc. (38I) stock a buy on weakness2025 Momentum Check & Stock Portfolio Risk Management - newser.com
Can a trend reversal in Intellia Therapeutics Inc. lead to recoveryJuly 2025 Breakouts & AI Enhanced Trade Execution Alerts - newser.com
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Is Intellia Therapeutics Inc. (38I) stock trading at attractive multiples2025 Dividend Review & Short-Term High Return Ideas - newser.com
Will Intellia Therapeutics Inc. (38I) stock benefit from sector leadershipWeekly Profit Summary & Long-Term Capital Growth Strategies - newser.com
Relative strength of Intellia Therapeutics Inc. in sector analysisTrade Signal Summary & AI Forecasted Entry/Exit Points - newser.com
Intellia Therapeutics (NTLA) Is Down 50.7% After FDA Halts MAGNITUDE Trials on Safety Concerns – Has The Bull Case Changed? - Sahm
Leerink Partnrs Has Positive Estimate for NTLA Q3 Earnings - MarketBeat
What to expect from Intellia Therapeutics Inc. in the next 30 days2025 Analyst Calls & Momentum Based Trading Signals - newser.com
Intellia Therapeutics Inc. (NTLA) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Intellia Stock Downgraded After Trial Pause Raises Safety Concerns, BofA Says - MarketScreener
SA analyst upgrades/downgrades: AMZN, NVDA, CMG, NTLA - Seeking Alpha
Liver Complications Lead FDA to Stop Tests of Intellia Gene-Editing Therapy for a Rare Disease - MedCity News
Intellia Therapeutics: Irreversible Edit Vs. Reversible SOCs Now A Hard Sell (Rating Downgrade) - Seeking Alpha
Gene-editing stocks rally on Bloomberg report that FDA plans to fast-track approval process - Sherwood News
FDA Clears Way for Faster Personalized Gene Editing Therapy - Bloomberg
NTLA FY2027 EPS Reduced by Brookline Capital Management - MarketBeat
What is Leerink Partnrs' Estimate for NTLA FY2027 Earnings? - MarketBeat
Is a relief rally coming for Intellia Therapeutics Inc. holders2025 Retail Activity & Free Real-Time Market Sentiment Alerts - newser.com
Is Intellia Therapeutics Inc. still worth holding after the dipJuly 2025 Sentiment & Long-Term Safe Investment Plans - newser.com
Analyzing drawdowns of Intellia Therapeutics Inc. with statistical tools2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
What technical models suggest about Intellia Therapeutics Inc.’s comeback2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
Will Intellia Therapeutics Inc. stock benefit from AI adoptionJobs Report & Growth Oriented Trading Recommendations - newser.com
Is Intellia Therapeutics Inc. stock oversold or undervaluedMarket Volume Summary & Free Technical Pattern Based Buy Signals - newser.com
Intellia Therapeutics Faces FDA Clinical Hold on Trials - The Globe and Mail
Intellia: Moving To 'Hold' Rating In Light Of Nex-Z Uncertainty In ATTR Patients (Downgrade) - Seeking Alpha
NTLA Stock: Plummet Unlocks Market Debate? - StocksToTrade
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Down 7.9% on Analyst Downgrade - MarketBeat
HC Wainwright & Co. Lowers NTLA Price Target to $18, Maintains B - GuruFocus
FDA places formal hold on two Intellia CRISPR trials - BioPharma Dive
FDA puts two Intellia CRISPR trials on hold following liver toxicity case - Endpoints News
Intellia Therapeutics (NASDAQ:NTLA) Lowered to "Hold" Rating by Wells Fargo & Company - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Rating Lowered to Sector Perform at Royal Bank Of Canada - MarketBeat
Life-Threatening Liver Toxicity Triggers FDA Freeze on Two Intellia Gene Therapy Studies - BioSpace
FDA places Intellia phase 3 CRISPR trials on hold over raised liver enzymes - Fierce Biotech
Biotech might be tiny but the dealmaking is mighty - statnews.com
Intellia Therapeutics stock price target lowered to $9 at Baird on FDA hold - Investing.com
Intellia falls as FDA places clinical hold on its gene therapy trials - TradingView
D.A. Davidson & CO. Grows Stock Holdings in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics (NTLA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Intellia Therapeutics Inc (NTLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.13%
1.73%
자본화:
|
볼륨(24시간):